IDH1 R132H — defines IDH-mutant astrocytoma (WHO 2021 grade 2-4) and oligodendroglioma (w...
Deterministic view of the source YAML entity. Clinical authority remains with the cited source IDs and reviewer sign-off state.
| ID | BMA-IDH1-R132H-GBM |
|---|---|
| Type | Actionability |
| Status | reviewed 2026-04-27 | pending_clinical_signoff | actionability review required |
| Diseases | DIS-GBM |
| Sources | SRC-CIVIC SRC-EANO-GBM-2024 SRC-NCCN-CNS-2025 |
Actionability Facts
| Biomarker | BIO-IDH-MUTATION |
|---|---|
| Variant | IDH1 R132H |
| Disease | DIS-GBM |
| ESCAT tier | IIA |
| Recommended combinations | vorasidenib monotherapy (low-grade IDH-mut), ivosidenib (high-grade IDH-mut, off-label/trial) |
| Evidence summary | IDH1 R132H — defines IDH-mutant astrocytoma (WHO 2021 grade 2-4) and oligodendroglioma (with 1p/19q codeletion). Vorasidenib improved PFS in residual/recurrent grade 2 IDH-mut glioma post- resection (INDIGO, Mellinghoff et al. NEJM 2023) — FDA-approved 2024. For grade 4 (IDH-mut GBM equivalent) — standard of care still RT + TMZ; ivosidenib explored. |
Notes
ESCAT IIA. OncoKB Level 2. IDH-mut GBM is a distinct entity from IDH-WT GBM and has better prognosis. R132H IHC is the standard screening test; non-canonical R132 require sequencing.
Used By
No reverse references found in the YAML corpus.